Emcure Pharmaceuticals (EMCURE.NS) Earnings Analysis
Emcure Pharmaceuticals (EMCURE.NS) has no confirmed upcoming earnings date. Last quarter (2026-02-04) it beat with EPS 12.4 INR vs 10.8 INR est (+14.8%). It has beaten estimates in 1/1 recent quarters (100%). Trailing P/E 38.32.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does EMCURE.NS next report earnings?
No confirmed upcoming earnings date is currently scheduled for EMCURE.NS. This page updates as the calendar is published.
EMCURE.NS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-02-04 | 12.4 INR | 10.8 INR | +14.8% | Beat |
Beat rate: 1/1 (100%) over reported quarters with consensus data.
EMCURE.NS valuation and analyst view
| Trailing P/E | 38.32 |
|---|---|
| Trailing EPS | 48.762 INR |
| Price / book | 7.16 |
| Dividend yield | 0.16% |
| Market cap | 358.34B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Emcure Pharmaceuticals (EMCURE.NS)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for EMCURE.NS. This page updates as the calendar is published.
Did EMCURE.NS beat earnings last quarter?
In its 2026-02-04 report, EMCURE.NS posted EPS of 12.4 INR versus a 10.8 INR estimate — a beat of 14.8%.
What is EMCURE.NS's earnings track record?
Over the last 1 reported quarters with consensus data, EMCURE.NS beat estimates 1 times (100%).
What is EMCURE.NS's current P/E ratio and EPS?
EMCURE.NS trades at a trailing P/E of 38.32 on trailing EPS of 48.76196153318633 INR.
What do analysts rate EMCURE.NS?
EMCURE.NS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.